Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of age in drug development and regulation, reflecting significant advances over the past 10 years in the predictability of key pharmacokinetic (PK) parameters from human in vitro data and in the availability of dedicated software platforms and associated databases. Specific advances and contemporary challenges with respect to predicting the processes of drug clearance, distribution, and absorption are reviewed, together with the ability to anticipate the quantitative extent of PK-based drug-drug interactions and the impact of age, genetics, disease, and formulation. The value of this capability in selecting and designing appropriate clinical studies, its implications for resource-sparing techniques, and a more holistic view of the application of PK across the preclinical/clinical divide are considered. Finally, some attention is given to the positioning of PBPK within the drug development and approval paradigm and its future application in truly personalized medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Contemporary PBPK platforms enable development teams to treat allometric scaling as a testable hypothesis embedded within mechanistic models, rather than as a standalone prediction tool [12,22,91].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [12]
In the citing paper
“uncertainty propagation through complex models can produce confidence intervals that under-represent true predictive uncertainty;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [12]
In the citing paper
“The integration of allometric priors with PBPK mechanistic refinement represents the current state of the art for interspecies translation, provided that these limitations are acknowledged and addressed during model qualification [12,23,84].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [12]
In the citing paper
“PBPK is not without its own failure modes: parameter identifiability can be poor when many tissue partition coefficients and enzyme abundances are simultaneously fitted from limited data;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [12]
In the citing paper
“overparameterization may yield apparent good fits without genuine predictive validity;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [12]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 946
Self-citationUtility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Self-citationEffect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., & Mamdani, M. M. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.082001 · Cited by 766
Research works printed but not linked: 10
- Teorell T., 1937, Arch. Int. Pharmacodyn. Ther., 57, 202
- Turner D, 2006, Drug Metab. Rev., 38, 162
- Webborn PJ, 2007, Xenobiotica, 37, 1090
- Gertz M, 2008, Drug Metab. Rev., 40, 92
- Rodgers T, 2006, Drug Metab. Rev., 38, 83
- Tucker GT., 1992, Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 550
- Shou M., 2005, Curr. Opin. Drug Discov. Dev., 8, 66
- Einolf HJ., 2007, Xenobiotica, 37, 1257
- 10.1177/0091270003252519 · doi:10.1177/0091270003252519 · Paper page
- 167. 2008. EMEA workshop on modeling in paediatric medicines . http://www.ema.europa.eu/meetings/conferences/1415apr08.htm
Cited by
The growing role of precision and personalized medicine for cancer treatment
Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., et al. (2018) · TECHNOLOGY · doi:10.1142/s2339547818300020 · Cited by 698
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
Metadata
- Authors
- Rowland, M., Peck, C., & Tucker, G.
- Affiliations
- University of Manchester (GB)
- University of California, San Francisco (US)
- Royal Hallamshire Hospital (GB)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2011-02-10
- Volume
- 51
- Issue
- 1
- Pages
- 45-73
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2109530280
- Cited by
- 662
- References
- 199
- Citations by year
- 2026: 41 · 2025: 27 · 2024: 28 · 2023: 19 · 2022: 46 · 2021: 39 · 2020: 37 · 2019: 39 · 2018: 32 · 2017: 40 · 2016: 50 · 2015: 58 · 2014: 50 · 2013: 67 · 2012: 55
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- physiologically based pharmacokinetic modeling, drug development, regulatory science, drug clearance, drug distribution, drug absorption, drug-drug interactions, in vitro-in vivo extrapolation, clinical trial design, personalized medicine, drug approval
- MeSH terms
- Animals, Clinical Trials as Topic, Computer Simulation, Drug and Narcotic Control, Drug Interactions, Pharmaceutical Preparations, Humans, Models, Biological, Pharmacokinetics, Drug Design, Drug Approval, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-010510-100540
- The paper
- Rowland, M., Peck, C., & Tucker, G. (2011). Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-010510-100540
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.